DEFA14A: OptiNose to be Acquired by Paratek Pharmaceuticals in $330 Million Deal

OptiNose, Inc. announces a definitive agreement to be acquired by Paratek Pharmaceuticals for $9 per share in cash, plus up to $5 per share in contingent value rights, potentially valuing the transaction at approximately $330 million.

Summary

• OptiNose has entered into a merger agreement with Paratek Pharmaceuticals.
• Paratek will acquire all outstanding shares of OptiNose for $9 per share in cash.
• There is also a contingent value right (CVR) of up to $5 per share based on XHANCE net sales milestones.
• The CVR includes $1 per share if XHANCE achieves $150M in net sales in any calendar year prior to December 31, 2028.
• An additional $4 per share is available if XHANCE achieves $225M in net sales in any calendar year prior to December 31, 2029.
• The total potential value of the transaction is approximately $330 million, or $14 per share.
• The transaction is expected to close in mid-2025, pending customary closing conditions.
• Paratek aims to leverage its primary care focus to expand the reach of XHANCE.
• An integration planning process will be launched involving members from both organizations.
• The definitive proxy statement will be mailed to the Company's stockholders in connection with the proposed transaction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition offers potential benefits for both companies, but there are also risks and uncertainties associated with the transaction.

Positives

• The acquisition provides OptiNose with access to Paratek's primary care promotional infrastructure, potentially expanding XHANCE's reach.
• The merger could lead to improved market penetration for XHANCE and better patient access.
• The transaction offers OptiNose shareholders a cash payment of $9 per share, with the potential for additional value through CVRs.
• Paratek's acquisition of XHANCE is an important first step in its evolution to becoming a pharmaceutical company with a differentiated, specialty-focused, multi-product commercial-stage portfolio.

Negatives

• The deal is subject to customary closing conditions, including shareholder approval, which introduces uncertainty.
• The CVR component is contingent on XHANCE achieving specific net sales milestones, which may not be met.
• The announcement of the merger or the consummation of the merger may have negative effects on the market price of the Company's common stock and on the Company's operating results.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to obtain necessary regulatory approvals could prevent the deal from closing.
• The occurrence of any event, change or other circumstances could give rise to the termination of the Merger Agreement.
• There is a risk that the milestones necessary for the payment of any contingent value rights may not be achieved.
• The pending Merger may make it more difficult to maintain business and operational relationships.
• The pending Merger may divert the Company management's attention from the ongoing business operations of its business.
• There is a risk of litigation, including shareholder litigation, and/or regulatory actions, related to the Merger.

Future Outlook

The document outlines the expectation that the transaction will close in mid-2025, pending customary conditions, and highlights the potential for expanded market reach for XHANCE through Paratek's primary care focus.

Management Comments

• Ramy A. Mahmoud, Chief Executive Officer of the Company, stated that Paratek's primary care focus is well suited to complement Optinose's existing specialty focus and to maximize the opportunity offered by XHANCE.
• The Optinose Management Team and our board of directors are extremely proud of your collective efforts to help XHANCE reach CS patients in need, and we are excited by the prospects for how a future integration with Paratek could advance our mission to improve lives for millions of patients with Chronic Sinusitis.

Industry Context

This acquisition reflects a trend of pharmaceutical companies seeking to expand their product portfolios and market reach through strategic mergers and acquisitions. Paratek's acquisition of OptiNose allows it to diversify its product offerings and gain access to the ENT/Allergy specialty market, while OptiNose benefits from Paratek's established primary care presence.

Comparison to Industry Standards

• Comparing this deal to other pharmaceutical acquisitions, the valuation multiple will depend on OptiNose's revenue and profitability, which are not detailed in this document.
• Similar deals in the pharmaceutical space often involve a combination of upfront cash payments and contingent value rights tied to product performance or regulatory milestones.
• The success of the acquisition will depend on the effective integration of the two companies and the ability to leverage Paratek's primary care infrastructure to drive XHANCE sales.

Stakeholder Impact

• Shareholders will receive $9 per share in cash, with the potential for additional value through CVRs.
• Employees may experience changes as a result of the integration of the two companies.
• Patients could benefit from expanded access to XHANCE through Paratek's primary care network.

Next Steps

• OptiNose will file preliminary and definitive proxy statements with the SEC.
• The definitive proxy statement will be mailed to the Company's stockholders.
• Stockholder vote to approve the acquisition.
• Launch of a formal integration planning process involving members from both organizations.
• Closing of the transaction, expected in mid-2025, pending customary conditions.

Key Dates

Keywords

acquisition, merger, OptiNose, Paratek, XHANCE, pharmaceuticals, contingent value rights, proxy statement